UFP-101 TFA

Cat. No.: HY-P1299A

Molecular Formula: $C_{84}H_{139}F_3N_{32}O_{23}$

Molecular Weight: 2022.19

Sequence Shortening: Bn-GGGFTGARKSARKRKNQ-NH2

Target: Opioid Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Sealed storage, away from moisture and light

Powder -80°C 2 years

-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Bn-GGGFTGARKSARKRKNQ-NH_2 (TFA salt)

SOLVENT & SOLUBILITY

In Vitro

H_2O : 130 mg/mL (64.29 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	0.4945 mL	2.4726 mL	4.9451 mL
5 mM	0.0989 mL	0.4945 mL	0.9890 mL
10 mM	0.0495 mL	0.2473 mL	0.4945 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

UFP-101 TFA is a potent, selective, and competitive antagonist of the N/OFQ peptide (NOP) receptor, with a pK_i of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioid receptors. UFP-101 TFA shows antidepressant-like effect[1][2].

In Vivo

UFP-101 TFA elicits a pronounced acute and dosedependent antidepressant-like effect in mice submitted to the forced swimming test (FST)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Calo G, et al. [Nphe^1,Arg^{14},Lys^{15}]nociceptin-NH_2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2002;136(2):303-311.

[2]. Gavioli EC, et al. Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test. Eur J Neurosci. 2003;17(9):1987-1990.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA